Pins matching place:Eastview

On 18 November 2011 the FDA approved Regeneron's EYLEA (aflibercept) Injection for wet age-related macular degeneration, dosed every eight weeks after three monthly injections, in a Priority Review.

On 24 February 2026 the FDA approved Dupixent for adults and children aged 6 and older with allergic fungal rhinosinusitis who have had sino-nasal surgery, the first medicine approved for the condition and the drug's ninth US indication area.

On 2 April 2026 the FDA approved extending EYLEA HD dosing intervals to every 20 weeks, up to 5 months, for wet age-related macular degeneration and diabetic macular edema after a year of successful response.

On 23 April 2026 the FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha, formerly DB-OTO), the first gene therapy for OTOF-related hearing loss, which Regeneron will supply free of charge in the US.

On 30 July 2026 Regeneron reported second-quarter revenue of US$4.3 billion, up 17%, with Dupixent global sales of US$6.0 billion, EYLEA HD US sales of US$596 million and non-GAAP EPS of US$14.29.

Regeneron said on 24 September 2026 it will report third-quarter 2026 financial and operating results on Friday 30 October before US markets open, with a conference call and webcast at 8:30 a.m. Eastern.

Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in symptomatic venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)